Klausner Richard
SEC insider (Form 3/4/5 filer). CIK 0001591178. Director at Lyell Immunopharma, Inc. (LYEL) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Jun 10, 2026. Located in CAMBRIDGE, MA.
Companies Klausner Richard has filed insider reports for
- Lyell Immunopharma, Inc. (LYEL): Director
- Parabilis Medicines, Inc. (PBLS): Director
Klausner Richard
CIK: 0001591178
Transaction Breakdown
Open Market Buys (P)1 (25.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (75.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 10, 2026LYEL
Lyell Immunopharma, Inc.
AwardDirectOption (right to buy)
9.3K shares- - Jun 9, 2026PBLS
Parabilis Medicines, Inc.
AwardDirectStock Option (Right to Buy)
20.2K shares- - May 15, 2025LYEL
Lyell Immunopharma, Inc.
AwardDirectOption (right to buy)
130K shares- - Mar 14, 2025LYEL
Lyell Immunopharma, Inc.
PurchaseIndirect158K shares at avg. $0.60$95K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 10, 2026 |  LYEL Lyell Immunopharma, Inc. | Award Option (right to buy) | 9,250 | - | - | Direct |
| Jun 9, 2026 |  PBLS Parabilis Medicines, Inc. | Award Stock Option (Right to Buy) | 20,215 | - | - | Direct |
| May 15, 2025 | LYEL Lyell Immunopharma, Inc. | Award Option (right to buy) | 130,000 | - | - | Direct |
| Mar 14, 2025 | LYEL Lyell Immunopharma, Inc. | Purchase | 158,000 | $0.60 | $94,942 | Indirect |
1-4 of 4 transactions